| P50 | author | Noriko Yamamoto-Mitani | Q57690528 |
| | Daisuke Takahari | Q87662858 |
| | Kensei Yamaguchi | Q87972994 |
| | Takeru Wakatsuki | Q88313362 |
| | Hiroki Osumi | Q89122610 |
| | Mitsukuni Suenaga | Q89170818 |
| | Izuma Nakayama | Q91785329 |
| | Eiji Shinozaki | Q96238224 |
| | Mariko Ogura | Q114405022 |
| | Keisho Chin | Q114405023 |
| P2093 | author name string | Hiroshi Kawachi | |
| | Naoki Hiki | |
| | Yuichi Ishikawa | |
| | Takashi Ichimura | |
| | Takeshi Sano | |
| | Tomohiro Matsushima | |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| | Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 |
| | Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients | Q27853121 |
| | Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 |
| | Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 |
| | Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine | Q28255790 |
| | Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 |
| | Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 |
| | HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer | Q30837184 |
| | Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 |
| | Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type | Q33779412 |
| | Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 |
| | p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity | Q36914246 |
| | Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial | Q36950483 |
| | Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 |
| | Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). | Q37632143 |
| | Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. | Q38936367 |
| | Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer | Q38951195 |
| | Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial | Q39668099 |
| | Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial | Q43712233 |
| | Clinical significance of intratumoral HER2 heterogeneity in gastric cancer | Q45406819 |
| | HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. | Q53251318 |
| | Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. | Q53604901 |
| | Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. | Q54218339 |
| | Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. | Q54224717 |
| | Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. | Q54321983 |
| | Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. | Q54402875 |
| | Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. | Q54483761 |
| | Clinical impact of a strategy involving endoscopic submucosal dissection for early gastric cancer: determining the optimal pathway | Q83426491 |
| | Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays | Q83789922 |
| | A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity | Q88055520 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 1186-1195 | |
| P577 | publication date | 2018-04-09 | |
| P1433 | published in | Journal of Gastroenterology | Q15764399 |
| P1476 | title | Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer | |
| P478 | volume | 53 | |